Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia.
Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.
Burnett
John R
JR
Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
D000818:Animals; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004341:Drug Evaluation; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000138:chemical synthesis / Q000302:isolation & purification* / Q000494:pharmacology
D002352:Carrier Proteins; D000960:Hypolipidemic Agents; C106092:microsomal triglyceride transfer protein